167 related articles for article (PubMed ID: 28606220)
1. Current and future strategies for the nutritional management of cardiometabolic complications of androgen deprivation therapy for prostate cancer.
Turner L; Poole K; Faithfull S; Griffin BA
Nutr Res Rev; 2017 Dec; 30(2):220-232. PubMed ID: 28606220
[TBL] [Abstract][Full Text] [Related]
2. The clinical importance of quantifying body fat distribution during androgen deprivation therapy for prostate cancer.
Foulkes SJ; Daly RM; Fraser SF
Endocr Relat Cancer; 2017 Mar; 24(3):R35-R48. PubMed ID: 28062546
[TBL] [Abstract][Full Text] [Related]
3. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
[TBL] [Abstract][Full Text] [Related]
4. [Androgen deprivation therapy and morbid obesity: do they share cardiovascular risk through metabolic syndrome?].
Cleffi S; Neto AS; Reis LO; Maia P; Fonseca F; Wroclawski ML; Neves M; Pompeo AC; Del Giglio A; Faria EF; Tobias-Machado M
Actas Urol Esp; 2011 May; 35(5):259-65. PubMed ID: 21459486
[TBL] [Abstract][Full Text] [Related]
5. A pilot randomised controlled trial of a periodised resistance training and protein supplementation intervention in prostate cancer survivors on androgen deprivation therapy.
Kiwata JL; Dorff TB; Todd Schroeder E; Salem GJ; Lane CJ; Rice JC; Gross ME; Dieli-Conwright CM
BMJ Open; 2017 Jul; 7(7):e016910. PubMed ID: 28698349
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a multi-component exercise programme and nutritional supplementation on musculoskeletal health in men treated with androgen deprivation therapy for prostate cancer (IMPACT): study protocol of a randomised controlled trial.
Owen PJ; Daly RM; Livingston PM; Mundell NL; Dalla Via J; Millar JL; Fraser SF
Trials; 2017 Oct; 18(1):451. PubMed ID: 28974267
[TBL] [Abstract][Full Text] [Related]
7. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis.
Bosco C; Bosnyak Z; Malmberg A; Adolfsson J; Keating NL; Van Hemelrijck M
Eur Urol; 2015 Sep; 68(3):386-96. PubMed ID: 25484142
[TBL] [Abstract][Full Text] [Related]
8. Metabolic sequelae associated with androgen deprivation therapy for prostate cancer.
Faris JE; Smith MR
Curr Opin Endocrinol Diabetes Obes; 2010 Jun; 17(3):240-6. PubMed ID: 20404727
[TBL] [Abstract][Full Text] [Related]
9. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
[TBL] [Abstract][Full Text] [Related]
10. 'First, do no harm': managing the metabolic impacts of androgen deprivation in men with advanced prostate cancer.
Lomax AJ; Parente P; Gilfillan C; Livingston PM; Davis ID; Pezaro C
Intern Med J; 2016 Feb; 46(2):141-8. PubMed ID: 25732203
[TBL] [Abstract][Full Text] [Related]
11. Metabolic complications of androgen deprivation therapy for prostate cancer.
Saylor PJ; Smith MR
J Urol; 2013 Jan; 189(1 Suppl):S34-42; discussion S43-4. PubMed ID: 23234628
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
Sentana-Lledo D; Morgans AK
Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
[TBL] [Abstract][Full Text] [Related]
13. Metabolic and cardiovascular effects of androgen deprivation therapy.
Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
15. Metabolic effects of androgen deprivation therapy.
Choi SM; Kam SC
Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
[TBL] [Abstract][Full Text] [Related]
16. Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.
Harrington JM; Schwenke DC; Epstein DR; Bailey DE
Oncol Nurs Forum; 2014 Jan; 41(1):21-9. PubMed ID: 24368236
[TBL] [Abstract][Full Text] [Related]
17. The effect of dietary interventions or patterns on the cardiometabolic health of individuals treated with androgen deprivation therapy for prostate cancer: A systematic review.
Wright HH; Walker MA; Broadbent S; Linton C; Keech JJ; Rune KT; Davis CL; Morris M; Zhang A; Newton RU; Marshall S
Maturitas; 2024 Jun; 184():107940. PubMed ID: 38430616
[TBL] [Abstract][Full Text] [Related]
18. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
19. Emerging cardiometabolic complications of androgen deprivation therapy.
Choong K; Basaria S
Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]